Revolution Medicines Inc header image

Revolution Medicines Inc

RVMD

Equity

ISIN null / Valor 52143299

NASDAQ (2026-11-03)
USD 194.23+3.22%

Revolution Medicines Inc
UMushroom community rating:

star star star star star
3.88 5 votes No rating yet
NegativeNeutralPositive

About company

Revolution Medicines is a clinical-stage biopharmaceutical company based in Redwood City, California, focused on discovering and developing small-molecule therapies that target the RAS/MAPK signaling pathway in cancer. The company pursues both direct inhibitors of oncogenic RAS mutants and agents that modulate RAS-dependent signaling nodes (for example, regulatory proteins upstream or downstream of RAS) using structure-guided and chemistry-driven approaches, and it advances multiple programs through preclinical and clinical development aimed at genetically defined tumor populations. Revolution Medicines operates within the precision oncology space, forming collaborations to support development and commercialization activities, and is publicly traded on the Nasdaq.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (22.10.2026):

Revolution Medicines Inc — Second Quarter 2026: Revolution Medicines Inc reported second-quarter 2026 results showing a transformational period driven by regulatory progress for daraxonrasib, strong liquidity after sizable financings, and materially higher R&D and commercial spending. The company announced FDA acceptance of the daraxonrasib NDA for previously treated metastatic pancreatic cancer, rapid Expanded Access Program distribution, and continued advancement of multiple Phase 3 programs while reporting a net loss for the quarter and updating full‑year operating expense guidance.

Regulatory and access milestones

FDA accepted the NDA for daraxonrasib for previously treated metastatic pancreatic adenocarcinoma (PDAC) following Phase 3 RASolute 302 results (OS and PFS benefits; NEJM publication). EMA initiated a phased review under the Cancer Medicines Pathfinder, Swissmedic granted Orphan Drug Status, and daraxonrasib was selected for the FDA Commissioner’s National Priority Voucher pilot. FDA also granted Breakthrough Therapy Designation to daraxonrasib in certain previously treated RAS‑mutant NSCLC.

Expanded Access & commercial readiness

The company opened a U.S. Expanded Access Program (EAP) in May and within three weeks distributed daraxonrasib to physicians for more than 2,000 patients across nearly all 50 states and Puerto Rico. Revolution built U.S. launch readiness and began phased EMA submissions and global commercial capability build‑out.

Clinical data highlights (PDAC & NSCLC)

Pivotal RASolute 302 showed statistically significant, clinically meaningful improvements in overall survival and PFS versus chemotherapy in previously treated PDAC. In NSCLC and frontline studies, zoldonrasib plus pembrolizumab/platinum chemo showed an ORR of ~82% (28 efficacy‑evaluable; DCR 100%), and elironrasib plus SOC showed a confirmed ORR of 85% (DCR 97%) with ~95% of patients progression‑free at 6 months (median follow‑up 8.7 months). These data support multiple ongoing/ planned global Phase 3 trials (e.g., RASolve 307/308/301/303/304/305/309).

Second-quarter financials

For the quarter ended June 30, 2026: R&D expense was $394.9 million; G&A was $110.2 million; total operating expenses $505.1 million. Net loss was $644.4 million (includes a $151.0 million non‑cash charge for change in fair value of warrants from the EQRx acquisition). Net loss per share was $(3.06) on a weighted‑average 210.9 million shares.

Balance sheet & liquidity

Cash, cash equivalents and marketable securities totaled $3.938 billion at June 30, 2026. Working capital was $3.674 billion, total assets $4.323 billion, total liabilities $1.717 billion, and stockholders’ equity $2.606 billion. The company notes up to an additional $1.5 billion in committed, flexible Royalty Pharma capital subject to milestones.

Financings & royalty funding

In April 2026 the company completed concurrent upsized offerings raising $1.725 billion of common stock and $500 million of convertible notes (gross $2.225 billion). In May 2026 Revolution received $250 million from Royalty Pharma for additional royalty rights (second tranche).

Guidance and outlook

Revolution Medicines updated full‑year 2026 GAAP operating expense guidance to $2.1–$2.2 billion, which includes estimated non‑cash stock‑based compensation of $270–$290 million. Key trial milestones and expected readouts include completion of RASolve 301 enrollment this year and an anticipated initial readout in 2027; other Phase 3 initiations and data updates were outlined through late 2026–2027.

Other items

Early‑stage programs continue (RMC‑5127 dose escalation with planned Phase 2 dose decision H2 2026; RM‑055 FIH expected Q4 2026). The company also highlighted clinical collaborations with Summit, Tango and Bristol Myers Squibb. A webcast to discuss results was scheduled for Aug 5, 2026 (archive available on the investor site).

Summarized from source with an LLMView Source

Key figures

227%1Y
776%3Y
487%5Y

Performance

61.4%1Y
57.1%3Y
61.6%5Y

Volatility

Market cap

41631 M

Market cap (USD)

Daily traded volume (Shares)

1,439,990

Daily traded volume (Shares)

1 day high/low

43.89 / 42.87

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

3.88

5 votes
Performance:
starstarstarstarstar
3.53
Innovation:
starstarstarstarstar
4.82
Society:
starstarstarstarstar
4.35
Nature:
starstarstarstarstar
4.00
Marcus Wang
UK, 20 Oct 2026
star star star star star
great innovation research
Dora Chen
UK, 19 Oct 2026
star star star star star
-
Mathias Charmoy
Switzerland, 01 May 2026
star star star star star
Great

EQUITIES OF THE SAME SECTOR

AMN Healthcare Services Inc
AMN Healthcare Services Inc AMN Healthcare Services Inc Valor: 1269241
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.03%USD 45.30
FibroGen Inc
FibroGen Inc FibroGen Inc Valor: 25953994
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.36%USD 4.31
Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals Inc Syndax Pharmaceuticals Inc Valor: 24112479
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
9.08%USD 14.29
Evolent Health Inc
Evolent Health Inc Evolent Health Inc Valor: 28153126
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.37%USD 4.30
ALX Oncology Holdings Inc
ALX Oncology Holdings Inc ALX Oncology Holdings Inc Valor: 55754366
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-5.84%USD 1.29
Hims & Hers Health Inc
Hims & Hers Health Inc Hims & Hers Health Inc Valor: 59397181
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.82%USD 25.70
Pacira BioSciences Inc
Pacira BioSciences Inc Pacira BioSciences Inc Valor: 12338490
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.03%USD 36.39
Ironwood Pharmaceuticals Inc
Ironwood Pharmaceuticals Inc Ironwood Pharmaceuticals Inc Valor: 10773079
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.16%USD 3.50
Addus HomeCare Corp
Addus HomeCare Corp Addus HomeCare Corp Valor: 10385048
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.64%USD 126.55
Arvinas Inc
Arvinas Inc Arvinas Inc Valor: 43526042
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-5.72%USD 7.09